Main Web Site : www.henderson-morley.com

On line shop web site : http://www.herpesexpert.com (Frost and Simpson)

Investor Relations email : investors@henderson-morley.com

Henderson Morley is a drug discovery company

The company has been developed specifically to carry out preliminary sourcing and screening of candidates to combat diseases caused by the herpes family of viruses and certain other DNA viruses

Latest GECR update 15th October 2006

Latest GE&CR update - 15th Oct 2006 :


The news investors have all been waiting for - regarding negotiations with a US dermatological pharmaceutical firm has finally been unveiled. The licence has been granted under an agreement to
Cutanea, a U.S. pharmaceutical company, specialising in the development of dermatology products in the US market.

The licence is for new applications of ICVT for the treatment of dermatological conditions in humans. The agreement and takes the form of an exclusive American, Mexican and Canadian wide licence to bring products to market through a programme of pre-clinical and clinical development of treatments either by Cutanea or through a sub-licence. Under the terms of the Agreement, Henderson Morley will receive up to 6.675 million dollars in development and commercialisation milestone payments up to the point at which the application receives regulatory approval, and will receive royalties on net sales thereafter.

Under its business plan, Henderson Morley has stated its belief that, following clinical development and regulatory licence approval, sales of the product in excess of $1.5 billion could be achieved over the subsequent ten year period. This would give a potential royalty to Henderson Morley in excess of $115 million over this term.

As a drug discovery company, it is imperative that Henderson continues to grant licenses to further develop its technology portfolio. This is the group's third ICVT license agreement. Encouragingly, Cutanea has a great management team with a proven track record of commercialising dermatology products.

Meanwhile, the company has announced that it has been working away on a vaccine against Koi Carp Herpes virus. The group believes it is now ready to start field trials of a
candidate vaccine, in a collaboration with the Internationally renowned Hagerman
Aquaculture Research Institute in Idaho USA. The initial immunogenicity studies should produce results within 6 months, enabling Henderson Morley scientists to optimise the vaccine formulation, with a view to securing a product licence from the veterinary authorities as soon as practicable.

Clearly activity at Henderson Morley has been significant in recent weeks. The licensing announcement is very encouraging, but with the news now out of the way, the shares have eased - a classic case of buy on the rumour, sell on the news. That said, the stock has now pulled back below the recent placing price. With so much going on at the company, further newsflow in the shorter term is far from unlikely.

*Henderson Morley is a corporate client of Bishopsgate Communications which is owned by RSH, the ultimate owner of GE&CR.

Forecasts and a formal recommendation are suspended ahead of the publication of a detailed note next month.

Haystack
This is true but so is this below; the sp will recover when there is more news. Still holding.


HENDERSON MORLEY PLC
(AIM)

STATEMENT ON SHARE PRICE MOVEMENT

The Board of Henderson Morley plc ('Henderson Morley' or 'the Company'), notes
the movement in the Company's share price today.

The Company is able to confirm that it is in a late stage of negotiations with an
AIM-listed life sciences company. This proposed collaboration may lead to the
grant of a licence in respect of another project from Henderson Morley's product
portfolio. A further statement will be made in this respect at the appropriate
time.

In fact the last time there was 'more news' about a deal the price fell as the news wasn't as good as expected. These types of deals take years to generate real profit. There is usually a product development phase first. It make well turn out to be a good company long term, but at the moment it is just sentiment driven as profits are a long, long way off.

Cynic - your posts are just a noise.

you mean like the warning bell? ...... you put your money where you like; if HML takes your fancy, then good luck to you, but be prepared to take a bath (even if, somewhat against the odds, it doesn't happen)

Sector
Biotech

Contact
Andrew Knight.
0121 442 4600


Henderson Morley has had an active month - something reflected in a n ear doubling of its share price.. The group has revealed it is in talks with a life sciences company and also unveiled interim figures.
The company confirmed on 12th January that it was in the late stage of negotiations with an AIM-listed life sciences company, the proposals of which, could lead to the grant of a licence in respect of another project from Henderson Morley's product portfolio. A further statement is expected in due course.
Meanwhile, interim numbers for the six months to 31st October were published on 16th January and showed a retained loss of 434,238 pounds, up from 352,204 pounds - a performance very much inline with expectations.
The company has now completed the Cutanea Licence Agreement for new applications of ICVT for the treatment of dermatological conditions in humans, including skin warts, verrucae and molluscum contagiosum. The Licence is an exclusive American, Mexican and Canadian wide licence to bring products to market through a programme of pre-clinical and clinical development of treatments either by Cutanea or through a sub-licence. Under the terms of the deal, Henderson Morley will receive up to 6.675 million dollars in development and commercialisation milestone payments up to the point at which the application receives regulatory approval, and will receive royalties on net sales thereafter. The Amistad License Agreement is for a new application of ICVT for the topical treatment of genital and labial herpes and certain other dysplasias.
With further details regarding the potential agreement with the life sciences company also a possibility in the short term, we expect the exciting pace of newsflow to continue. We continue to believe that the share price doers not reflect what is already known at a corporate level and will be publishing a new formal valuation shortly.
*Henderson Morley is a corporate client of Bishopsgate Communications which is owned by RSH, the ultimate owner of GE&CR.
Forecasts and a formal recommendation are suspended ahead of the publication of a detailed note next month.


http://www.bishopsgatecommunications.com/ourClients.htm

Morning
On the move, could we have news today
keith

kkeith2000
Tipped by brokers as under valued 6p IMO short term.

Driver, How do you know this?

Looks like RNS Today.

is 2.60/2.80 the correct/typical spread? ..... if so, that's a big move required just to break even.

of (much) better quality (still checking them out) are Southern Cross and Caretech

is this the announcement?

Don't think it is - but nonetheless shows what value there is in this share

All looks good to me; another ASM in the making after all the volatility has gone the sp will steadily grow over the coming months as the news comes in.

Driver I Agree ,all looks very exciting.

yet again good news comes out & as usual pump & dump. Can't understand as this company looks like a clear winner over the next few years.

fact ..... the market does not like, or perhaps does not trust this company to perform ...... if you fancy the sector, then better to look at quality like Caretech or Southern Cross

From the UPS thread.......

(Added by Master RSI on Mon 12 Feb 09:54 pm)

HML - Mid 2.325p
Reason - Chart looking ready for a BREAKOUT from a Symmetrical Triangle formed during the last month also the Indicators are at oversold and now rising, allways expecting news of their vaccine research with a GECR report on their findings

Indicators chart

Strange that @ Present you can sell 600,000 HML @ 2.29 & only buy 37,500 2.45 online anyone have any theorys as to why?

Market's short of stock, I'd say. But they don't want to put the price up to acquire it.